BACKGROUND: Men with familial prostate cancer and African American men are at risk for developing prostate cancer at younger ages. Genetic markers predicting early-onset prostate cancer may provide clinically useful information to guide screening strategies for high-risk men. We evaluated clinical information from six polymorphisms associated with early-onset prostate cancer in a longitudinal cohort of high-risk men enrolled in prostate cancer early detection with significant African American participation. METHODS: Eligibility criteria include ages 35 to 69 with a family history of prostate cancer or African American race. Participants undergo screening and biopsy per study criteria. Six markers associated with early-onset prostate cancer [rs2171492 (7q32), rs6983561 (8q24), rs10993994 (10q11), rs4430796 (17q12), rs1799950 (17q21), and rs266849 (19q13)] were genotyped. Cox models were used to evaluate time to prostate cancer diagnosis and prostate-specific antigen (PSA) prediction for prostate cancer by genotype. Harrell's concordance index was used to evaluate predictive accuracy for prostate cancer by PSA and genetic markers. RESULTS: Four hundred and sixty participants with complete data and ≥ 1 follow-up visit were included. Fifty-six percent were African American. Among African American men, rs6983561 genotype was significantly associated with earlier time to prostate cancer diagnosis (P = 0.005) and influenced prediction for prostate cancer by the PSA (P < 0.001). When combined with PSA, rs6983561 improved predictive accuracy for prostate cancer compared with PSA alone among African American men (PSA = 0.57 vs. PSA + rs6983561 = 0.75, P = 0.03). CONCLUSIONS: Early-onset marker rs6983561 adds potentially useful clinical information for African American men undergoing prostate cancer risk assessment. Further study is warranted to validate these findings. IMPACT: Genetic markers of early-onset prostate cancer have potential to refine and personalize prostate cancer early detection for high-risk men.
BACKGROUND:Men with familial prostate cancer and African American men are at risk for developing prostate cancer at younger ages. Genetic markers predicting early-onset prostate cancer may provide clinically useful information to guide screening strategies for high-risk men. We evaluated clinical information from six polymorphisms associated with early-onset prostate cancer in a longitudinal cohort of high-risk men enrolled in prostate cancer early detection with significant African American participation. METHODS: Eligibility criteria include ages 35 to 69 with a family history of prostate cancer or African American race. Participants undergo screening and biopsy per study criteria. Six markers associated with early-onset prostate cancer [rs2171492 (7q32), rs6983561 (8q24), rs10993994 (10q11), rs4430796 (17q12), rs1799950 (17q21), and rs266849 (19q13)] were genotyped. Cox models were used to evaluate time to prostate cancer diagnosis and prostate-specific antigen (PSA) prediction for prostate cancer by genotype. Harrell's concordance index was used to evaluate predictive accuracy for prostate cancer by PSA and genetic markers. RESULTS: Four hundred and sixty participants with complete data and ≥ 1 follow-up visit were included. Fifty-six percent were African American. Among African American men, rs6983561 genotype was significantly associated with earlier time to prostate cancer diagnosis (P = 0.005) and influenced prediction for prostate cancer by the PSA (P < 0.001). When combined with PSA, rs6983561 improved predictive accuracy for prostate cancer compared with PSA alone among African American men (PSA = 0.57 vs. PSA + rs6983561 = 0.75, P = 0.03). CONCLUSIONS: Early-onset marker rs6983561 adds potentially useful clinical information for African American men undergoing prostate cancer risk assessment. Further study is warranted to validate these findings. IMPACT: Genetic markers of early-onset prostate cancer have potential to refine and personalize prostate cancer early detection for high-risk men.
Authors: Julie A Douglas; Kimberly A Zuhlke; Jennifer Beebe-Dimmer; Albert M Levin; Stephen B Gruber; David P Wood; Kathleen A Cooney Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-08 Impact factor: 4.254
Authors: Ethan M Lange; Claudia A Salinas; Kimberly A Zuhlke; Anna M Ray; Yunfei Wang; Yurong Lu; Lindsey A Ho; Jingchun Luo; Kathleen A Cooney Journal: Prostate Date: 2011-05-02 Impact factor: 4.104
Authors: Albert M Levin; Mitchell J Machiela; Kimberly A Zuhlke; Anna M Ray; Kathleen A Cooney; Julie A Douglas Journal: Cancer Res Date: 2008-08-15 Impact factor: 12.701
Authors: Jennifer L Beebe-Dimmer; Albert M Levin; Anna M Ray; Kimberly A Zuhlke; Mitchell J Machiela; Bronwen A Halstead-Nussloch; Gregory R Johnson; Kathleen A Cooney; Julie A Douglas Journal: Int J Cancer Date: 2008-06-15 Impact factor: 7.396
Authors: Veda N Giri; Jennifer Beebe-Dimmer; Mark Buyyounouski; Andre Konski; Steven J Feigenberg; Robert G Uzzo; Gerald Hanks; Andrew K Godwin; David Y T Chen; Robert Gordon; Terrence Cescon; Susan Raysor; Deborah Watkins-Bruner Journal: J Urol Date: 2007-09-17 Impact factor: 7.450
Authors: Rosalind A Eeles; Zsofia Kote-Jarai; Graham G Giles; Ali Amin Al Olama; Michelle Guy; Sarah K Jugurnauth; Shani Mulholland; Daniel A Leongamornlert; Stephen M Edwards; Jonathan Morrison; Helen I Field; Melissa C Southey; Gianluca Severi; Jenny L Donovan; Freddie C Hamdy; David P Dearnaley; Kenneth R Muir; Charmaine Smith; Melisa Bagnato; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Beatrice N Gehr-Swain; Rosemary A Wilkinson; Angie Cox; Sarah Lewis; Paul M Brown; Sameer G Jhavar; Malgorzata Tymrakiewicz; Artitaya Lophatananon; Sarah L Bryant; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Cyril Fisher; Charles Jamieson; Colin S Cooper; Dallas R English; John L Hopper; David E Neal; Douglas F Easton Journal: Nat Genet Date: 2008-02-10 Impact factor: 38.330
Authors: Cheryl D Cropp; Christiane M Robbins; Xin Sheng; Anselm J M Hennis; John D Carpten; Lyndon Waterman; Ronald Worrell; Tae-Hwi Schwantes-An; Jeffrey M Trent; Christopher A Haiman; M Cristina Leske; Suh-Yuh Wu; Joan E Bailey-Wilson; Barbara Nemesure Journal: Prostate Date: 2014-09-22 Impact factor: 4.104
Authors: Shannon M Lynch; Elizabeth Handorf; Kristen A Sorice; Elizabeth Blackman; Lisa Bealin; Veda N Giri; Elias Obeid; Camille Ragin; Mary Daly Journal: PLoS One Date: 2020-08-13 Impact factor: 3.240